Physician profile
Yuan Lu
NPI 1952300857
$1,806.12
in general payments reported to CMS, 2019-2025
21 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2021: $29.82 · 2022: $115 · 2023: $522 · 2024: $676 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453 · Education: $53.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.53 |
| Education | $53.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $211.39 | 2019-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals Lp | $193.59 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $180.37 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $152.21 | 2023-2025 | |
| Horizon Therapeutics Plc | $131.44 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $131.07 | 2022-2024 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $102.43 | 2024-2025 | |
| Travere Therapeutics, INC. | $92.53 | 2022-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $91.11 | 2023-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $83.04 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Calliditas Therapeutics US INC. | $81.63 | 2025 | Tarpeyo |
| Vifor Pharma, INC. | $73.00 | 2023-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.55 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $62.32 | 2023-2024 | Ultomiris |
| Opko Pharmaceuticals, LLC | $37.48 | 2019-2023 | Rayaldee |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Ani Pharmaceuticals, INC. | $20.64 | 2023 | Purified Cortrophin Gel |
| Lilly USA, LLC | $17.85 | 2023 | Jardiance |
| Mallinckrodt Hospital Products INC. | $17.05 | 2021 | |
| Novo Nordisk INC | $15.82 | 2025 | |
| Ardelyx, INC. | $13.99 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuan Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.